BRAF and pleomorphic xanthoastrocytoma: Here, we report a case of a patient with a longstanding history of a primary brain tumor, a Pleomorphic Xanthoastrocytoma (PXA), BRAF V600E mutated WHO grade 2-3, who developed CSF spread and has been outstandingly controlled with a combination of B-raf (BRAF) and Mitogen-activated protein kinase (MEK) inhibitors (BRAF/MEKi) for over 3 years.